Skip to main content

Table 2 Correlation of toxicities and tumor shrinkage with percentage change in plasma biomarkers

From: Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

Plasma Biomarker n Hypertension Proteinuria Fatigue Tumor Shrinkage
r P Value r P Value r P Value r P Value
IL-6 19 0.19 .421 0.247 .294 -0.173 .465 -0.437 .061
IL-8 19 -0.077 .748 0.053 .823 0.002 .993 -0.191 .434
IL-10 19 0.158 .505 0.038 .872 0.141 .552 -0.392 .097
VEGF 19 0.569 .008b 0.703 <.001a 0.529 .016c -0.277 .250
PDGF-BB 19 -0.215 .363 -0.151 .524 0.043 .857 -0.277 .250
HGF 25 0.624 <.001a 0.615 <.001a 0.431 .027c -0.235 .257
SCF 25 0.145 .478 0.176 .390 -0.057 .780 0.261 .207
SDF1α 25 0.257 .204 0.314 .117 0.344 .085 0.424 .034c
sVEGFR1 25 -0.38 .055 -0.365 .066 0.065 .753 0.038 .855
sVEGFR2 25 -0.613 <.001a -0.601 .001b -0.466 .016c -0.431 .031c
  1. The concentrations of plasma proteins were measured at baseline and at day 8 of lenvatinib treatment, and the percentage change from baseline was analyzed (Spearman’s correlation analysis) in correlation with toxicities and tumor shrinkage. Worst grade of toxicities and maximum tumor shrinkage over the duration of treatment were used for the analysis.
  2. a P < 0.001.
  3. b P < 0.01.
  4. c P < 0.05.